

2023-2027 Egypt Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers-Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

https://marketpublishers.com/r/22FC5C19C132EN.html

Date: September 2023 Pages: 0 Price: US\$ 2,000.00 (Single User License) ID: 22FC5C19C132EN

Abstracts

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years.The report is available by section, and can be customized to specific information needs and budget.The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.



Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Cancer Diagnostic Tests Analyzed in the Report--over 200 current and emerging assays, including Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines and Immunohistochemical Stains, such as:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.



Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.Partial Table of Contents

Introduction

Market Overview

Major Product Development Opportunities

Design Criteria for New Products

Alternative Market Penetration Strategies

Potential Market Entry Barriers and Risks

Major Current and Emerging Diagnostic Tests

Instrumentation Review and Market Needs

Current and Emerging Technologies

Market Size, Supplier Shares, Test Volume and Sales Segment Forecasts

Competitive Profiles and Strategies

2023-2027 Egypt Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyze...



Contents

I. INTRODUCTION

II. MARKET OVERVIEW

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

VII. MAJOR CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS

- 1. Introduction
- 2. Cancer Diagnostic Classification
- 3. ACTH
- 4. Alpha-Fetoprotein (AFP)
- 5. Beta-2 Microglobulin
- 6. CA 15-3/27.29
- 7. CA 19-9
- 8. CA-125
- 9. Calcitonin
- 10. Carcinoembrionic Antigen (CEA)
- 11. Estrogen and Progesterone Receptors
- 12. Ferritin
- 13. Gastrin
- 14. Human Chorionic Gonadotropin (HCG)
- 15. Insulin
- 16. NSE
- 17. Occult Blood

2023-2027 Egypt Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyze...





- 18. PAP Smear/HPV
- 19. Prostatic Acid Phosphatase (PAP)
- 20. Prostate-Specific Antigen (PSA)
- 21. Squamous Cell Carcinoma Antigen (SCC)
- 22. T and B Lymphocytes
- 23. TdT
- 24. Thyroglobulin
- 25. Tissue Polypeptide Antigen (TPA)
- 26. Biochemical Cancer Diagnostics
- 27. Oncogenes

 : :Abl/abl-bcr

 : :AIB1

 : :BCL-2

 : :BRCA1

 : :CD44

 : :C-fos

 : :C-myb

 : :C-myc

- : :CYP-17
- : :Erb-B
- : :HPC1
- : :N-myc
- : :P40
- : :P51
- : :P53

 : :PIK3CA

- : :PTI-1
- : :Ras
- : :Reg
- : :Sis
- : :Src and others
- 28. Polypeptide Growth Factors
- : :Basic Fibroblast Growth Factor
- : :Beta-TGF
- : :Cachectin (TNT)
- : :Calmodulin
- : :ECFR
- : :Nerve Growth Factor (NGF)

 : :Epidermal Growth Factor (EGF)



 : :Ornithine Decarboxylase : :Transferrin : :Transforming Growth Factor-Alpha 29. Ectopic Hormones 30. Colony Stimulating Factors 31. Lymphokines : :Alpha-Interferon : :B Cell Growth Factors : :B Cell Growth Factor (BCGF) : :Gamma-Interferon : :Interleukin-1 (IL-1) : :Macrophage Activating Factor 32. Immunohistochemical Stains 33. Emerging Cancer Diagnostics : :N-Acetylglucosamine : :Actin : :Alpha-Actin : :Antineuronal Antibodies : :7B2 : :B72.3 : :Bax : :BCD-F9 : :BLCA-4 : :Blood Group Antigens A,B,H : :CA : :CA 72-4/TAG-72 : :CA : :CA-242 : :CA-549 : :CAM : :CAR-3 : :Cathepsin-D : :Chromogranin A and B : :Cluster 1 Antigen : :Cluster-5/5A Antigen : :CTA : :CU18 : :DR-70 : :DU-PAN-2



- : :Endometrial Bleeding Associated Factor
- : :Endostatin
- : :Epithelial Membrane Antigen
- : :Feulgen Hydrolysis
- : :Fibronectin
- : :FSH
- : :(1-\$\$\$3)-L-fucosyltransferase
- : :Gastrin-Releasing Peptide (GRP)
- : :GDCFP-15
- : :Glucagon
- : :Glycoamines
- : :H23
- : :Her-2
- : :Human Carcinoma Antigen
- : :HPA
- : :HSP27
- : :Intermediate Filaments
- : :Cytokeratins/CK18/Cyfra 21-1
- : :Desmin
- : :Gliofibrillary Acid Protein
- : :Neurofilaments
- : :Vimentin
- : :KA
- : :Kinases
- : :KP16D3
- : :LAI
- : :Leukocyte Common Antigen
- : :Lewis Antigens
- : :Lysophosphatidic Acid (LPA)
- : :Ma 695/Ma
- : :MABDF3
- : :MAG
- : :ME1
- : :Minactivin
- : :MN/CA9
- : :MSA
- : :Mucin Cancer Antigen (MCA)
- : :Multiple Tumor Suppressor
- : :Myosin



 : :NEA-130

- : :NMP22
- : :OA-519
- : :Opiod Peptides
- : :P-glycoprotein
- : :Pancreatic Oncofetal Antigen (POA)
- : :Placental Lactogen
- : :PR92
- : :Proliferative Index, Ki-67
- : :Px
- : :RB Inactivation/Deletion
- : :Ret
- : :SCCL
- : :Selectin
- : :Sialic Acid
- : :Sialyl SSEA-1/SLX
- : :SN10
- : :Somatostatin
- : :TA-90
- : :TABA
- : :Tachykinin
- : :TAG
- : :TPS
- : :Troponin
- : :Tubulin
- : :VCAM
- : :VEGF
- : :Villen and others

VIII. INSTRUMENTATION REVIEW AND MARKET NEEDS

IX. CURRENT AND EMERGING TECHNOLOGIES

- 1. Monoclonal and Polyclonal Antibodies
- 2. Immunoassays
- 3. Molecular Diagnostics
- 4. Chromosome Analysis
- a. Chronic Myelogenous Leukemia (CML)



- b. Acute Myeloid Leukemia (AML)
- c. Acute Lymphoblastic Leukemia (ALL)
- d. Malignant Lymphomas Lymphoid Malignancies
- e. Chronic Lymphocytic Leukemia (CLL)
- f. Solid Cancers
- g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies

X. MARKET SIZE, TEST VOLUME AND SALES FORECASTS

XI. COMPETITIVE PROFILES

The report provides strategic assessments of over 30 leading cancer diagnostics market players and

start-up companies with innovative technologies and products, including:

 : :Abbott

 : :Affymetrix

 : :Beckman Coulter/Danaher/Cepheid

 : :Becton Dickinson

 : :bioMerieux

 : :Bio-Rad

 : :DiaSorin

 : :Eiken Chemical

 : :Elitech Group

 : :Enzo Biochem

 : :Fuifilm Wako

 : :Fujirebio

 : :Grifols

 : :Hologic

 : :Leica Biosystems

 : :PerkinElmer

 : :Qiagen

 : :QuidelOrtho

 : :Roche

2023-2027 Egypt Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyze...



 : :Siemens Healthineers : :Takara Bio : :Thermo Fisher and others.



List Of Tables

LIST OF TABLES

Cancer Diagnostic Test Volume and Sales Forecasts Cancer Diagnostic Volume Forecast by Test Cancer Diagnostics Sales Forecast by Test ACTH Test Volume and Diagnostics Sales Forecast AFP Test Volume and Diagnostics Sales Forecast Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast CA 15-3/27.29 Test Volume and Diagnostics Sales Forecast CA 19-9 Test Volume and Diagnostics Sales Forecast CA-125 Test Volume and Diagnostics Sales Forecast Calcitonin Test Volume and Diagnostics Sales Forecast Cathepsin Test Volume and Diagnostics Sales Forecast **CEA Test Volume and Diagnostics Sales Forecast** Chromogranin Test Volume and Diagnostics Sales Forecast Colon-specific Antigen Test Volume and Diagnostics Sales Forecast Cytokeratins Test Volume and Diagnostics Sales Forecast Estrogen Receptor Test Volume and Diagnostics Sales Forecast Ferritin Test Volume and Diagnostics Sales Forecast Gastrin Test Volume and Diagnostics Sales Forecast HCG Test Volume and Diagnostics Sales Forecast Insulin Test Volume and Diagnostics Sales Forecast Interferons Test Volume and Diagnostics Sales Interleukins Test Volume and Diagnostics Sales Forecast Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast NSE Test Volume and Diagnostics Sales Forecast Nucleolar Test Volume and Diagnostics Sales Forecast Occult Blood Test Volume and Diagnostics Sales Forecast Oncogenes Test Volume and Diagnostics Sales Forecast Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast PAP Smear Test Volume and Diagnostics Sales Forecast Parathyroid Hormone Test Volume and Diagnostics Sales Forecast Progesterone Receptor Test Volume and Diagnostics Sales Forecast PAP Test Volume and Diagnostics Sales Forecast **PSA Test Volume and Diagnostics Sales Forecast** S-100 Protein Test Volume and Diagnostics Sales Forecast Serotonin Test Volume and Diagnostics Sales Forecast



Sialic Acid Test Volume and Diagnostics Sales Forecast Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast **TDT Test Volume and Diagnostics Sales Forecast** Thymidine Kinase Test Volume and Diagnostics Sales Forecast Thyroglobulin Test Volume and Diagnostics Sales Forecast **TPA Test Volume and Diagnostics Sales Forecast Cancer Diagnostic Classification** Major Companies Developing or Marketing ACTH Tests Major Companies Developing or Marketing AFP Tests Major Companies Developing or Marketing Beta-2 Microglobulin Tests Major Companies Developing or Marketing CA 15-3/27.29 Tests Major Companies Developing or Marketing CA 19-9 Tests Major Companies Developing or Marketing CA 125 Tests Major Companies Developing or Marketing Calcitonin Tests Major Companies Developing or Marketing CEA Tests Major Companies Developing or Marketing Estrogen Receptor Tests Major Companies Developing or Marketing Progesterone Receptor Tests Major Companies Developing or Marketing Ferritin Tests Major Companies Developing or Marketing Gastrin Tests Major Companies Developing or Marketing HCG Tests Major Companies Developing or Marketing Insulin Tests Major Companies Developing or Marketing NSE Tests Major Companies Developing or Marketing Occult Blood Tests Major Companies Developing or Marketing PAP Smear/HPV Tests Major Companies Developing or Marketing PAP Tests Major Companies Developing or Marketing PSA Tests Major Companies Developing or Marketing Lymphocyte Sub-classification Tests **Biochemical Markers Potential Applications in Cancer Diagnosis Oncogenes Potential Applications in Cancer Diagnosis** Major Companies Developing or Marketing Oncogene Tests Growth Factors Potential Applications in Cancer Diagnosis Colony Stimulating Factors Potential Applications in Cancer Diagnosis Lymphokines Potential Applications in Cancer Diagnosis Immunohistochemical Stains Potential Applications in Cancer Diagnosis



I would like to order

- Product name: 2023-2027 Egypt Tumor Markers Testing Market-High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers-Supplier Shares and Strategies, Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers
 - Product link: https://marketpublishers.com/r/22FC5C19C132EN.html
 - Price: US\$ 2,000.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/22FC5C19C132EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature ____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>



To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970